IP Library › Granted Patent US 12,269,869
Granted Patent B2
US 12,269,869 · App. 17/461,365 · Granted Apr 8, 2025

Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof

Inventors: Travis S. Young (La Jolla, CA); Leonard Presta (La Jolla, CA); David Rodgers (La Jolla, CA); Eric Hampton (La Jolla, CA); Timothy Wright (La Jolla, CA); Peter G. Schultz (La Jolla, CA); Eduardo Laborda (La Jolla, CA); Elvira Khialeeva (La Jolla, CA); Sophie Viaud (La Jolla, CA)
Assignee: The Scripps Research Institute
C07K16/18A61P35/00C07K14/7051C07K14/70517C07K14/70521C07K14/70578C07K16/2803A61K2039/507C07K2317/24C07K2317/34C07K2317/55C07K2317/565C07K2317/622C07K2317/73C07K2317/76C07K2317/92C07K2319/02C07K2319/03C07K2319/30C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,269,869
App. No.
17/461,365
Granted
Apr 8, 2025
Kind
B2
Abstract

The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.

Claims (26)

1. A chimeric antigen receptor-effector cell (CAR-EC) expressing a humanized chimeric antigen receptor (CAR), wherein the humanized CAR comprises an extracellular domain, a transmembrane domain, and an intracellular signaling domain; wherein the extracellular domain comprises a humanized anti-GCN4 scFv comprising light chain CDRs 1-3 and heavy chain CDRs 1-3, respectively, set forth as GSSTGAVTTSNYAS (SEQ ID NO: 425), GTNNRAP (SEQ ID NO:426), VLWYSDHWV (SEQ ID NO:427), GFLLTDYGVN (SEQ ID NO:428), VIWGDGITD (SEQ ID NO:429), and GLFDY (SEQ ID NO:430).

2. The CAR-EC of claim 1 , which is a T cell.

3. The CAR-EC of claim 1 , wherein the scFv comprises the amino acid sequence set forth in SEQ ID NO: 322.

4. The CAR-EC of claim 1 , wherein the CAR comprises a sequence selected from SEQ ID NOS: 401, 403, 405, 407, 409, 411, 413, and 415.

5. The CAR-EC of claim 2 , wherein the CAR comprises the amino acid sequence set forth in SEQ ID NO: 411.

6. The CAR-EC of claim 1 , wherein the extracellular domain comprises a hinge domain, wherein the hinge domain comprises a sequence selected from SEQ ID NOS: 93-103, 165-168, and 424.

7. The CAR-EC of claim 1 , wherein the transmembrane domain comprises an amino acid sequence at least 95% identical to the sequence set forth in SEQ ID NO: 417.

8. The CAR-EC of claim 1 , wherein the intracellular signaling domain comprises: a CD3-zeta domain and a CD28 domain; a 4-1BB domain; or a CD28 domain and a 4-1BB domain.

9. The CAR-EC of claim 8 , wherein the CD28 domain comprises an amino acid sequence at least 95% identical to the sequence set forth in SEQ ID NO: 418.

10. The CAR-EC of claim 8 , wherein the 4-1BB domain comprises an amino acid sequence at least 95% identical to the sequence set forth in SEQ ID NO: 419.

11. The CAR-EC of claim 8 , wherein the CD3-zeta domain comprises an amino acid sequence at least 95% identical to the sequence set forth in SEQ ID NO: 420.

12. A chimeric antigen receptor-effector cell (CAR-EC) platform, comprising (1) a CAR-EC of claim 1 , and (2) a CAR-EC switch; wherein the CAR-EC switch comprises (a) a chimeric antigen receptor-interacting domain (CAR-ID) comprising a GCN4 derivative peptide that interacts with the anti-GCN4 scFv in the chimeric antigen receptor on the CAR-EC, wherein the GCN4 derivative peptide comprises a sequence set forth in any one of SEQ ID NOS: 26, 36, 139-163 and 245; and (b) a humanized targeting antibody or antigen binding portion thereof that comprises a light chain variable region/heavy chain variable region sequence pair selected from (i) SEQ ID NO: 30/SEQ ID NO: 7; (ii) SEQ ID NO: 30/SEQ ID NO: 6; (iii) SEQ ID NO: 34/SEQ ID NO: 6; and (iv) SEQ ID NO: 34/SEQ ID NO: 7.

13. The CAR-EC platform of claim 12 , wherein the humanized targeting antibody or antigen binding portion thereof of the CAR-EC switch comprises a light chain variable region/heavy chain variable region sequence pair selected from (i) SEQ ID NO: 30/SEQ ID NO: 7, and the CAR of the CAR-EC comprises the amino acid sequence set forth in SEQ ID NO: 411.

14. A method of treating a subject afflicted with a disease or condition in which CD19 + cells are implicated in pathology, comprising administering to the subject a CAR-EC platform of claim 12 .

15. A polynucleotide encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular domain, a transmembrane domain, and an intracellular signaling domain; wherein the extracellular domain comprises a humanized anti-GCN4 scFv comprising light chain CDRs 1-3 and heavy chain CDRs 1-3 respectively set forth as GSSTGAVTTSNYAS (SEQ ID NO:425), GTNNRAP (SEQ ID NO:426), VLWYSDHWV (SEQ ID NO:427), GFLLTDYGVN (SEQ ID NO:428), VIWGDGITD (SEQ ID NO:429), and GLFDY (SEQ ID NO:430).

16. A vector comprising the polynucleotide of claim 15 .

17. A chimeric antigen receptor-effector cell (CAR-EC) switch comprising:

a. chimeric antigen receptor-interacting domain (CAR-ID) comprising a GCN4 derivative peptide that comprises a sequence set forth in any one of SEQ ID NOS: 26, 36, 139-163 and 245; and

b. a humanized anti-CD19 targeting antibody or antigen binding portion thereof that comprises (1) a light chain variable region sequence selected from any one of SEQ ID NOS: 16-25, 27-35, 247, 249, 251, 253, 255, 257, 259, 261, 263, 265, and 267; and (2) a heavy chain variable region sequence selected from any one of SEQ ID NOS: 1-15, 248, 250, 252, 254, 256, 258, 260, 262, 264, 266, and 268.

18. The CAR-EC switch of claim 17 , wherein the humanized anti-CD19 targeting antibody or antigen binding portion thereof comprises (1) a light chain variable region sequence selected from the group consisting of SEQ ID NOS: 16-25 and 27-35, and (2) a heavy chain variable region sequence selected from the group consisting of SEQ ID NOS: 1-15.

19. The CAR-EC switch of claim 17 , wherein the targeting antibody or antigen binding portion thereof is a scFv.

20. The CAR-EC switch of claim 17 , wherein the humanized anti-CD19 targeting antibody comprises (1) a light chain variable region sequence set forth in SEQ ID NO: 30, and (2) a heavy chain variable region sequence set forth in SEQ ID NO: 7.

21. The CAR-EC switch of claim 17 , wherein the humanized anti-CD19 targeting antibody comprises a light chain variable region/heavy chain variable region sequence pair selected from (i) SEQ ID NO: 30/SEQ ID NO: 7; (ii) SEQ ID NO: 30/SEQ ID NO: 6; (iii) SEQ ID NO: 34/SEQ ID NO: 6; and (iv) SEQ ID NO: 34/SEQ ID NO: 7.

22. The CAR-EC switch of claim 17 , wherein the GCN4 peptide is fused to the N terminus of the light chain variable region sequence.

23. A polynucleotide encoding the CAR-EC switch of claim 17 .

24. A vector comprising the polynucleotide of claim 23 .

Continuity (3)
Continuation 16343353
Provisional Application 62410315 · Oct 19, 2016
Related Publication 20220073597A1 · Mar 10, 2022
References Cited (27)
US 11091546B2 · Young · 2021 [cited by examiner]
US 11174306B2 · Young · 2021 [cited by examiner]
US 20130287748A1 · June et al. · 2013 [cited by applicant]
US 20150079088A1 · Lowman · 2015 [cited by examiner]
US 20150307564A1 · Young et al. · 2015 [cited by applicant]
US 20190169289A1 · Young et al. · 2019 [cited by applicant]
US 20210116455A1 · Brinkmann · 2021 [cited by examiner]
US 20210238291A1 · Lowman · 2021 [cited by examiner]
US 20220041736A1 · Kufer · 2022 [cited by examiner]
WO 2015057834A1 · 2015 [cited by applicant]
WO 2015057852A1 · 2016 [cited by applicant]
WO 2016054520A2 · 2016 [cited by applicant]
WO 2016168773A2 · 2016 [cited by applicant]
Zahnd et al (J Biol Chem. Apr. 30, 2004; 279(18):18870-7. doi: 10.1074/jbc.M309169200. Epub Jan. 30, 2004). [cited by examiner]
Rodgers et al (Proc Natl Acad Sci U S A. Jan. 26, 2016;113(4):E459-68. doi: 10.1073/pnas.1524155113. Epub Jan. 12, 2016.). [cited by examiner]
Almagro & Franssen, Frontiers in Bioscience, 13:1619-33 (2008). [cited by examiner]
Marchalonis et al., Dev & Comp Immunol. 30:223-247 (2006). [cited by examiner]
Lippow et al., Nature Biotechnology, 25(10):1171-1176 (2007). [cited by examiner]
Hasegawa et al., MABS, vol. 9, No. 5, pp. 854-873 (2017). [cited by examiner]
Altshuler et al., Biochemistry (Moscow), 75(13):1584-1605 (2010). [cited by examiner]
Vajda et al., Current Opinion in Structural Biology, 67 pp. 226-231 (2021). [cited by examiner]
Marks et al., J. Biol. Chem. 295(29) 9823-9837 (2020). [cited by examiner]
Akbar et al., Cell Reports 34, 108856, Mar. 16, 2021. [cited by examiner]
Lo et al., BMC Genomics vol. 22, Article No. 116 (2021). [cited by examiner]
Zahnd, C., et al., The Journal of Biological Chemistry 279(18), 18870-18877; Epub Jan. 30, 2004; Apr. 30, 2004). [cited by examiner]
Rodgers et al., “Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies”, PNAS, vol. 113, No. 4, Jan. 26, 2016 pp. E459-E468. [cited by applicant]
Cao et al., “Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer”, Angewandte Chemie International Edition, May 4, 2016, vol. 55, No. 26, pp. 7520-7524. [cited by applicant]